



WHAT IS CLAIMED IS:

1. Substantially pure ETM-305, having the following structure:




ETM 305

2. Substantially pure ETM-204, having the following structure:



ETM 204

3. Substantially pure ETM-775 having the following structure:



ETM 775

4. A method of treating mammalian leukemia in patients in need of such treatment, said method comprising administering an effective amount of ETM-305 to said patient in unit dosage form.
5. A method of treating mammalian leukemia in patients in need of such treatment, said method comprising administering an effective amount of ETM-775 to said patient in unit dosage form.
6. A method of treating mammalian lung carcinoma in patients in need of such treatment, said method comprising administering an effective amount of ETM-305 to said patient in unit dosage form.
7. A method of treating mammalian lung carcinoma in patients in need of such treatment, said method comprising administering an effective amount of ETM-775 to said patient in unit dosage form.
8. A method of treating mammalian colon adenocarcinoma in patients in need of such treatment, said method comprising administering an effective amount of ETM-305 to said patient in unit dosage form.
9. A method of treating mammalian colon adenocarcinoma in patients in need of such treatment, said method comprising administering an effective amount of ETM-775 to said patient in unit dosage form.
10. A method of treating mammalian malignant melanoma in patients in need of such treatment, said method comprising administering an effective amount of ETM-305 to said patient in unit dosage form.
11. A method of treating mammalian malignant melanoma in patients in need of such treatment, said method comprising administering an effective

12. A pharmaceutical composition comprising ETM-305 and a pharmaceutically acceptable carrier, diluent or excipient.

13. A pharmaceutical composition comprising ETM-775 and a pharmaceutically acceptable carrier, diluent or excipient.

14. A method of assaying the human cytochrome CYP3A4 metabolism of ecteinascidin 743, comprising monitoring a test sample for the presence of one or more metabolites selected from the group consisting of ETM-204, ETM-305 and ETM-775.